A clinical trial conducted by UC-San Diego has found that COMPASS Pathways' synthetic psilocybin COMP360 treatment could potentially be used to treat anorexia nervosa. The study found that a single 25-milligram dose of COMP360, paired with psychological support, led to significant reductions in eating disorder psychopathology in 40% of participants, three months post-administration. The treatment also led to reductions in shape and weight concerns, an increase in body mass index (BMI) in 50% of participants, and more positive feelings about life in 90% of participants. COMPASS intends to build on these promising results with a larger Phase 2 clinical study.